Related Experiment Video

Updated: May 26, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia

Srinivasa Subramaniam1, Francesco Napolitano, Robert G Mealer

  • 1The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Nature Neuroscience
|December 20, 2011
PubMed

Insights

Ras homolog enriched in striatum (Rhes) protein activates mTOR signaling, causing L-DOPA-induced dyskinesia in Parkinson's disease therapy. Inhibiting Rhes may reduce side effects while maintaining treatment efficacy.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • L-DOPA is a primary treatment for Parkinson's disease.
  • L-DOPA-induced dyskinesia is a significant side effect limiting treatment.
  • Mammalian target of rapamycin (mTOR) signaling in the striatum mediates this dyskinesia.

Purpose of the Study:

  • To investigate the role of Ras homolog enriched in striatum (Rhes) in L-DOPA-induced dyskinesia.
  • To determine if Rhes interacts with and modulates mTOR signaling.
  • To evaluate the therapeutic potential of targeting Rhes for Parkinson's disease treatment.

Main Methods:

  • Utilized Rhes knockout (Rhes(-/-)) mice.
  • Assessed striatal mTOR signaling pathways.
  • Evaluated motor function and dyskinesia in response to L-DOPA treatment.

Main Results:

  • Rhes binds to and activates mTOR in the striatum.
  • Rhes(-/-) mice exhibited reduced striatal mTOR signaling.
  • Rhes deficiency diminished L-DOPA-induced dyskinesia without compromising motor improvements.

Conclusions:

  • Rhes is a key mediator of L-DOPA-induced dyskinesia via mTOR activation.
  • Targeting Rhes represents a promising therapeutic strategy to mitigate Parkinson's disease treatment side effects.
  • Rhes-binding drugs could offer a way to improve L-DOPA therapy outcomes.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...